Clinical trials: Seizures Disorders
Epilepsy
Lyrica (Pregabalin) Administered as an Add-on Therapy for Partial Seizures (LEADER).
The objective of study is to assess the clinical improvement (change in seizure frequency), safety, and tolerability of subjects with partial seizures following adjunctive therapy of pregabalin BID (150 to 600 mg/day titration)…
- Trial name
- LEADER (NCT00288639)
- Testing
- Pregabalin
- Where
- 8 sites in Greece
- Volunteers
- 98 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Photosensitive Epilepsy
A Study to Evaluate the Pharmacodynamic Activity of E2730 in Adult Participants With Photosensitive Epilepsy
The primary purpose of the study is to assess the pharmacodynamic (PD) activity of E2730 as measured by suppression of epileptic photoparoxysmal response (PPR) in the participant's most sensitive eye condition in participants…
- Trial name
- NCT03603639
- Testing
- E2730
- Where
- 5 sites in United States
- Volunteers
- 6 people
- Sponsor
- Eisai Inc.
Refractory Partial Seizures
A Long-term Extension Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-Epileptic Drugs (AEDs)
The purpose of this trial is to investigate the safety and tolerability of perampanel in long- term treatment in the patients with refractory partial epilepsy (uncontrolled with other anti-epileptic drugs) who completed Week 10…
- Trial name
- NCT00903786
- Testing
- perampanel
- Where
- 9 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Eisai Co., Ltd.
Epilepsy, Generalized Tonic-clonic Seizures
An Open Label Study of L059 (Levetiracetam) in Japanese Epilepsy Subjects With Generalized Tonic-clonic Seizures
The investigators will provide Levetiracetam treatment to epilepsy subjects in Japan who are judged to benefit from continued treatment with Levetiracetam by the investigators and who are willing to continuously receive this drug.
- Trial name
- NCT01398956
- Testing
- Levetiracetam
- Where
- 32 sites in Japan
- Volunteers
- 44 people
- Sponsor
- UCB Pharma
Epilepsy
Assess Safety and Efficacy of Lacosamide in Patients With Partial Seizures
The main purpose of this trial is to determine safety and efficacy of Lacosamide under long term therapy.
- Trial name
- NCT00515619
- Testing
- Lacosamide
- Where
- 54 sites in Australia, Croatia and 11 more
- Volunteers
- 376 people
- Sponsor
- UCB Pharma
Tuberous Sclerosis Complex, Epilepsy
Safety and Efficacy of AV078 in Participants With Tuberous Sclerosis Complex (TSC) Refractory Epilepsy (RESTOR-1)
This Phase 2, randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability, and efficacy of oral AV078 in participants with refractory epilepsy due to tuberous sclerosis complex (TSC).
- Trial name
- RESTOR-1 (NCT07680322)
- Testing
- AV078
- Where
- Canada
- Volunteers
- 42 people
- Sponsor
- Aeovian Pharmaceuticals, Inc.
Epilepsy
A Study to Assess Tolerability and Efficacy of Topiramate Monotherapy in Recently Diagnosed Patients With Epilepsy
The purpose of this dose optimization study is to assess tolerability and efficacy of topiramate monotherapy in recently diagnosed patients with epilepsy who are treatment naive or have failed one anti-epileptic drug (AED)…
- Trial name
- NCT01689649
- Testing
- Topiramate
- Where
- 2 sites in Vietnam
- Volunteers
- 139 people
- Sponsor
- Janssen Research & Development, LLC
Quality of Life, Epilepsy (treatment Refractory)
Evaluation of the Epilepsy-related Quality of Life, Seizure-related Accidents and Validation of the Mjn-SERAS Solution in the Normalised Patient Environment with Real-World Data
The study will be prospective, multicentre, postmarketing clinical study, with a controlled and randomized design, to perform the analysis of 130 subjects with a clinical diagnosis of epilepsy, patients whose clinical semiology…
- Trial name
- SERAS_Home_RWD (NCT05845255)
- Testing
- mjn-SERAS
- Where
- 6 sites in Germany, Spain and 1 more
- Volunteers
- 130 people
- Sponsor
- MJN Neuroserveis, S.L
Epilepsy, Epilepsy in Children
XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy
To investigate the potential antiseizure effects of adjunctive XEN496 (ezogabine) compared with placebo in children with KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE).
- Conditions
- Epilepsy, Epilepsy in Children, Epilepsy; Seizure, Disease
- Trial name
- EPIK (NCT04639310)
- Testing
- XEN496
- Where
- 20 sites in United States, Australia and 3 more
- Volunteers
- 8 people
- Sponsor
- Xenon Pharmaceuticals Inc.
Epilepsy
Levetiracetam Versus Topiramate as Adjunctive Therapy to Evaluate Efficacy and Safety in Subjects With Refractory Partial Onset Seizures
To assess the long-term effects of levetiracetam on retention rate in subjects with refractory partial onset seizure that are not fully controlled with 1 to 3 concomitant antiepileptic drugs, compared to topiramate as add-on…
- Trial name
- NCT01229735
- Testing
- Levetiracetam, Topiramate
- Where
- 24 sites in South Korea
- Volunteers
- 343 people
- Sponsor
- UCB Korea Co., Ltd.
Generalized Convulsive Epilepsy
Study to Evaluate the Safety and Efficacy of Levetiracetam in Patients Suffering From Idiopathic Generalized Epilepsy With Primary Generalized Tonic-clonic Seizures
This study will assess the efficacy, safety, and tolerability of adjunctive treatment with LEV (3,000 mg/day or a target dose of 60 mg/kg/day in children) compared to placebo in reducing PGTC seizures in subjects (4 - 65 years)…
- Trial name
- NCT00160550
- Testing
- Levetiracetam
- Volunteers
- 154 people
- Sponsor
- UCB Pharma
GRIN-related Disorders
Honeycomb: Evaluation of Radiprodil in Children with GRIN-related Disorder
Study RAD-GRIN-101 is a phase 1B trial to assess safety, tolerability, PK, and potential efficacy of radiprodil for the treatment of GRIN-related disorder in children with a Gain-of-Function (GoF) genetic variant.
- Trial name
- NCT05818943
- Testing
- Radiprodil
- Where
- 15 sites in United States, Australia and 6 more
- Volunteers
- 24 people
- Sponsor
- GRIN Therapeutics, Inc.
Epilepsy
Patients With Epilepsy Taking LAMICTAL Immediate-Release Who Switch To Extended-Release Formulation And Vice Versa
Pharmacokinetic (PK) study to characterize changes in serum concentrations in epilepsy patients when switching from LAMICTAL immediate-release to extended-release and vice versa.
- Trial name
- NCT00264615
- Testing
- lamotrigine extended-release
- Where
- 12 sites in United States
- Volunteers
- 45 people
- Sponsor
- GlaxoSmithKline
Epilepsy, Seizures
Impact of Capturing Ictal Events With Ultra-long-term Ambulatory EEG Monitoring With Remote EEG Monitoring System.
The goal of this clinical trial is to test Epitel's™ Remote EEG Monitoring System's (REMI™) ability to record electroencephalography (EEG) of seizure events in an ambulatory setting for extended periods (14 - 28 days) in patients…
- Trial name
- REMI (NCT06027749)
- Testing
- Epitel's™ Remote EEG Monitoring System's (REMI™)
- Where
- 2 sites in United States
- Volunteers
- 65 people
- Sponsor
- Epitel, Inc.
Developmental and Epileptic Encephalopathy
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)
This (DEEp OLE Study) is a multicentre, open-label study to investigate the long-term safety, efficacy, tolerability, and pharmacokinetics (PK) of LP352 in the treatment of seizures in children and adults with DEE who completed…
- Trial name
- NCT06908226
- Testing
- LP352
- Where
- 88 sites in United States, Australia and 15 more
- Volunteers
- 324 people
- Sponsor
- Longboard Pharmaceuticals
Nonconvulsive Status Epilepticus, Seizures
Does Use of Rapid Response EEG Impact Clinical Decision Making
This study is designed as a prospective, non-randomized, observational, multicenter clinical trial. The primary aim of this study is to observe if the use of the rapid responds electroencephalography (EEG) system impacts…
- Trial name
- DECIDE (NCT03534258)
- Testing
- Ceribell Rapid Response EEG, Survey
- Where
- 5 sites in United States
- Volunteers
- 164 people
- Sponsor
- Ceribell Inc.
Motor Seizures
Study of Algorithm for Epilepsy Alert Device
An accelerometer with transmitting ability is worn on the wrist. Data of movements during seizures will be analyzed to upgrade algorithm that will identify seizures.
- Trial name
- NCT00497835
- Volunteers
- 15 people
- Sponsor
- Biolert
Epilepsy
Study of Retigabine Immediate Release as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial-Onset Seizures
The purpose of this Phase III study is to evaluate the efficacy, safety and tolerability and health outcomes of retigabine Immediate Release (IR) as adjunctive therapy to each of the following monotherapy Antiepileptic Drug (AED)…
- Trial name
- IR (NCT01227902)
- Testing
- Retigabine IR
- Where
- 66 sites in Belgium, Bulgaria and 10 more
- Volunteers
- 203 people
- Sponsor
- GlaxoSmithKline
Focal Epilepsy
Anti-Epilepsy Medication Valproate Administered Via ICV Route and Catheters and Pumps for CSF Infusion
This is a non-randomized open-label extension study for subjects having completed protocol DA071976 or CLN100P.01.
- Trial name
- NCT04529954
- Testing
- Valproic Acid delivered to ICV
- Where
- 8 sites in Australia, Israel
- Volunteers
- 20 people
- Sponsor
- Cerebral Therapeutics LLC
Epilepsy
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
The main purpose of this study is to evaluate the effectiveness of the study drug lacosamide (200-600 mg/day) when added to a stable dose of levetiracetam (1000-3000 mg/day) with withdrawal of the concomitant sodium channel…
- Trial name
- VERVE (NCT01484977)
- Testing
- Lacosamide
- Where
- 54 sites in United States, Australia and 7 more
- Volunteers
- 120 people
- Sponsor
- UCB Pharma